|Last Price$328.00||Day Change (%)1.73%|
|Open Price$323.13||Day Change ($)5.59|
|Day Range321.15–328.32||52-Week Range207.48–328.32|
As of Mon 01/26/2015 08:00 PM EST | USD
UPDATE: Major U.S. benchmarks challenge last-ditch support
Celgene's stock rises, but off highs after profit outlook
As the sector has continued to best the broader market, a look both at the dynamics that would drive further outperformance by the sector and at funds that investors can use to tap those themes.
Biotech companies' returns have diverged from the broader market in recent weeks amid concerns over greater regulation and price discounting.
This article represents opinions of the author and not those of his firm and are subject to change from time to time and do not constitute a recommendation to purchase and sale any security nor to engage in any particular investment strategy. The information contained here has been obtained from ...
The five biotech ETFs have very different portfolios with markedly different performance.
Jerry Slusiewicz depends on his own analysis and risk-management philosophy to keep client portfolios in order.
ETFs are gathering assets amid the market malaise.
A roundup of investment news from Morningstar Advisor magazine.